LL-37: The Antimicrobial Peptide for Chronic Infections & Biofilms (2026)

Affiliate Disclosure: PeptideOnline.co participates in affiliate programs. Some links are affiliate links — we may earn a commission at no extra cost to you. All recommendations are based on independent evaluation.

What Is LL-37?

LL-37 (also called Cathelicidin) is the only human cathelicidin antimicrobial peptide — a 37-amino acid molecule that serves as a frontline component of the innate immune system. It's produced by white blood cells, epithelial surfaces, and barrier tissues throughout the body, providing broad-spectrum antimicrobial defense against bacteria, viruses, and fungi.

What makes LL-37 particularly interesting for chronic infection research is its ability to disrupt biofilms — the protective structures that bacteria form to shield themselves from antibiotics and the immune system. Biofilm-protected infections are notoriously difficult to treat and are implicated in conditions from chronic Lyme to SIBO to chronic sinusitis.

The Biofilm Angle: Up to 80% of chronic bacterial infections involve biofilms. Standard antibiotics often can't penetrate biofilm structures. LL-37 has demonstrated the ability to disrupt biofilm formation and enhance antibiotic penetration in research settings.

Mechanism of Action

Direct antimicrobial: LL-37 disrupts bacterial cell membranes through electrostatic interaction with negatively charged phospholipids, creating pores that kill the organism
Biofilm disruption: Prevents biofilm formation and can disrupt established biofilms, exposing protected bacteria to immune cells and antibiotics
Immune modulation: Recruits immune cells to infection sites, promotes wound healing, and modulates inflammatory responses
Antiviral activity: Research shows activity against enveloped viruses through membrane disruption
Antifungal: Demonstrated activity against Candida species in research settings

Research Applications

Chronic Lyme & Tick-Borne Infections

Borrelia burgdorferi (the Lyme disease pathogen) forms biofilms that protect it from antibiotics. LL-37's biofilm-disrupting properties make it a research target for chronic Lyme protocols. Some integrative practitioners explore LL-37 alongside antimicrobial therapy to improve treatment penetration.

SIBO (Small Intestinal Bacterial Overgrowth)

SIBO involves bacterial colonization in the small intestine where bacteria shouldn't proliferate. LL-37's antimicrobial activity in the gut, combined with its biofilm disruption capabilities, makes it relevant for SIBO research — particularly recurrent cases resistant to antibiotic treatment.

CIRS (Chronic Inflammatory Response Syndrome)

CIRS involves persistent inflammatory activation often triggered by biotoxin exposure (mold, Lyme). LL-37's dual antimicrobial and immunomodulatory properties are relevant because it can address both pathogen burden and inflammatory dysregulation.

Wound Healing & Skin Infections

As a natural component of skin immunity, LL-37 promotes wound healing while providing antimicrobial protection at the wound site. Research has explored its use in chronic wound management and burn treatment.

Regulatory Status: LL-37 is FDA Category 2 as of 2026, meaning it faces restrictions on compounding access. It is available from research peptide suppliers. The limited human safety data contributed to its Category 2 classification.

Research Protocols

Application	Dose	Route	Duration
Antimicrobial support	50-100 mcg SC	Subcutaneous	4-8 weeks alongside antimicrobial therapy
Biofilm disruption	50-100 mcg SC	Subcutaneous	Variable — often pulsed with antibiotic cycles
Gut/SIBO	Research stage	SC or experimental oral	Protocol-dependent

LL-37 in Stacking Context

With Thymosin Alpha-1: LL-37 provides direct antimicrobial action while Tα1 optimizes the adaptive immune response. Different layers of immune support. Tα1 guide →
With BPC-157 / KPV: For gut-focused protocols. LL-37 addresses pathogen burden, BPC-157 heals damaged tissue, KPV reduces inflammation. Gut protocol →

Where to Source LL-37

BioPure Peptides

Code: POWER

LL-37 10mg vials available.

Shop LL-37 →

Safety Considerations

Limited human safety data — primary evidence from in vitro and animal studies
Category 2 peptide — regulatory caution warranted
At high concentrations, LL-37 can be cytotoxic to human cells (dose matters)
Some research suggests LL-37 may promote angiogenesis in certain contexts — potential concern for individuals with active cancer
Should only be used under provider supervision, particularly in chronic infection protocols

Frequently Asked Questions

What does LL-37 do?

LL-37 is the human body's natural antimicrobial peptide. It kills bacteria, disrupts biofilms, fights viruses and fungi, and modulates immune responses. It's particularly relevant for chronic infections where biofilm-protected bacteria resist standard antibiotics.

Is LL-37 legal?

LL-37 is FDA Category 2 as of 2026, meaning it faces compounding restrictions. It is available from research peptide suppliers for laboratory use.

Can LL-37 help with Lyme disease?

LL-37's biofilm-disrupting properties make it a research target for chronic Lyme, where Borrelia burgdorferi forms protective biofilm structures. It's explored as an adjunct to antimicrobial therapy, not a standalone treatment.

What is a biofilm?

A biofilm is a protective matrix that bacteria create around themselves, shielding them from antibiotics and the immune system. Up to 80% of chronic bacterial infections involve biofilms, which is why chronic infections are so difficult to treat.

Not Sure Which Peptide Is Right for You?

Take our free 60-second quiz and get personalized recommendations based on your goals.

Take the Quiz →